Heart failure secondary to chronic lung disease; cardiac arrhythmias; brain tumor; acute alcoholism; delirium tremens; idiosyncrasy to the drug; convulsive states (eg, status epilepticus, tetanus, strychnine poisoning).
Depressant effects of morphine may be enhanced.
May need to reduce dose.
View all 100 images.
Monitor for increased CNS and respiratory depression when administered with morphine. Additive CNS depression.
Dosage reduction may be necessary.
Monitor patient for at least 24 h after initial dose because of reports of severe adverse reactions with epidural/intrathecal use. Improper substitution of Infumorph for regular Duramorph may result in serious overdose. Category C.
Data sources include Micromedex (updated Sep 26th, 2014), Cerner Multum (updated Oct 16th, 2014), Wolters Kluwer (updated Oct 9th, 2014) and others. To view content sources and attributions, refer to our editorial policy.
2009 Wolters Kluwer Health.
narcotic analgesics tramadol, oxycodone, hydrocodone, fentanyl, methadone, Dilaudid.
PO 10 to 30 mg every 4 h as needed. Avinza 45 to 120 mg once daily only in opioid-tolerant patients. Subcutaneous/IM 5 to 20 mg/70 kg every 4 h as needed. IV 2.5 to 15 mg per 70 kg in water for injection 4 to 5 mL over 5 min as needed. IV (open-heart surgery) 0.5 to 3 mg/kg. IV (MI pain) 8 to 15 mg; for very severe pain, additional smaller doses may be given every 3 to 4 h. PR 10 to 20 mg every 4 h as needed. Epidural Initial injection of 5 mg may provide pain relief for up to 24 h; if pain is not controlled within 1 h, give incremental doses of 1 to 2 mg. Do not exceed 10 mg per 24 h. Intrathecal Usual dose is 10% of epidural dose. Single injection of 0.2 to 1 mg may provide pain relief for 24 h. Do not inject more than 2 mL of 5 mg per 10 mL ampule or 1 mL of 10 mg per 10 mL ampule. Repeat injections not recommended.
Today the final DEA rule on switching hydrocodone combination products like Lortab and Vicodin from schedule III to schedule II comes into effect. This rule.
The U.S. Food and Drug Administration today approved new labeling for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, an.
Infection at injection site; anticoagulation; bleeding condition; parenteral corticosteroids within past 2 wk; any other drug or condition that would contraindicate intrathecal/epidural therapy.
Hypersensitivity to opiates; upper airway obstruction; acute asthma; diarrhea caused by poisoning or toxins.
Increased amylase and lipase may occur up to 24 h after dose.
Duramorph - Injection 0.5 mg/mL - Injection 1 mg/mL.
Roxanol Rescudose - Solution 10 mg per 2.5 mL.
Store at room temperature (59° to 86°F).
provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Oramorph SR - Tablets, controlled-release 15 mg - Tablets, controlled-release 30 mg - Tablets, controlled-release 60 mg - Tablets, controlled-release 100 mg.
Miosis, respiratory and CNS depression, circulatory collapse, seizures, cardiopulmonary arrest, death.
May need to reduce dose.
MS Contin - Tablets, controlled-release 15 mg - Tablets, controlled-release 30 mg - Tablets, controlled-release 60 mg - Tablets, controlled-release 100 mg - Tablets, controlled-release 200 mg.
Relief of moderate to severe acute and chronic pain; relief of pain in patients who require opioid analgesics for more than a few days (sustained-release only); management of pain not responsive to nonnarcotic analgesics; dyspnea associated with acute left ventricular failure and pulmonary edema; preoperative sedation; adjunct to anesthesia; analgesia during labor.
Pregnancy Category C Risk cannot be ruled out.
MSIR - Solution 10 mg per 5 mL - Solution 20 mg per 5 mL - Solution 20 mg/mL.
Follow: Google+ Facebook Twitter YouTube RSS.
Nausea; vomiting; constipation; abdominal pain.
Respiratory depression; apnea; respiratory arrest; laryngospasm; depression of cough reflex.
Infumorph - Injection 10 mg/mL - Injection 25 mg/mL.
Availability Rx Prescription only.
Avinza - Capsules, extended-release 30 mg - Capsules, extended-release 45 mg - Capsules, extended-release 60 mg - Capsules, extended-release 75 mg - Capsules, extended-release 90 mg - Capsules, extended-release 120 mg.
RMS - Rectal Suppositories 5 mg - Rectal Suppositories 10 mg - Rectal Suppositories 20 mg - Rectal Suppositories 30 mg.
Use drug with caution in patients with myxedema, acute alcoholism, acute abdominal conditions, ulcerative colitis, decreased respiratory reserve, head injury or increased intracranial pressure, hypoxia, supraventricular tachycardia, depleted blood volume or circulatory shock.
Subcutaneous/IM 0.1 to 0.2 mg/kg every 4 h. 15 mg.
Astramorph PF - Injection 0.5 mg/mL - Injection 1 mg/mL.
Virtually all converted into glucuronide metabolites; small fraction is demethylated in the liver. Major metabolite is morphine-3-glucuronide (55% to 75%).
Duration is 3 to 7 h.
Mean T max is 3.7 h and mean C max is 9.9 to 27.4 ng/mL (dose dependent) for sustained-release form. Bioavailability is approximay 40%
Roxanol T - Solution 20 mg/mL.
Onset is 15 to 60 min (intrathecal/epidural).
Precipitation of IV solutions.
We comply with the HONcode standard for trustworthy health information. Verify here.
Kadian - Capsules, sustained-release 20 mg - Capsules, sustained-release 50 mg - Capsules, sustained-release 100 mg.
Safety and efficacy not established.
Relieves pain by stimulating opiate receptors in CNS; also causes respiratory depression, peripheral vasodilation, inhibition of intestinal peristalsis, sphincter of Oddi spasm, stimulation of chemoreceptors that cause vomiting and increased bladder tone.
OMS Concentrate - Solution 20 mg/mL.
Urinary retention or hesitancy.
Excreted in breast milk.
Monitor for increased respiratory and CNS depression. Concomitant administration of cimetidine and morphine has been reported to precipitate apnea, confusion, and muscle twitching in an isolated report.
The t ½ is approximay 2 to 4 h.
Approval History Calendar Drug history at FDA.
Chronic Pain tramadol oxycodone Cymbalta Percocet fentanyl duloxetine methadone Dilaudid morphine OxyContin Ultram More.
Giving a common local anesthetic to women undergoing breast removal surgery -- a mastectomy -- reduces their risk of persistent pain after the procedure, a new.
Hypotension; orthostatic hypotension; bradycardia; tachycardia; palpitations.
Bisulfites and morphine may potentiate each other, preventing use by cause severe adverse reactions. Has abuse potential.
Tolerance; psychological and physical dependence with chronic use; pain at injection site; local irritation and induration following subcutaneous use.
Roxanol UD - Solution 10 mg per 2.5 mL - Solution 20 mg per 5 mL - Solution 30 mg per 1.5 mL.
Therapeutic morphine doses have increased duration of labor.
Lightheadedness; dizziness; drowsiness; sedation; euphoria; dysphoria; delirium; disorientation; incoordination. Sweating; pruritus; urticaria. Blurred vision; miosis.
Roxanol - Solution 20 mg/mL.
Respiratory insufficiency; severe CNS depression; heart failure secondary to chronic lung disease; cardiac arrhythmias; increased intracranial or cerebrospinal pressure; head injuries; brain tumor; acute alcoholism; delirium tremens; convulsive disorders; after biliary tract surgery; suspected surgical abdomen; surgical anastomosis; idiosyncrasy to the drug; concomitantly with MAOIs or within 14 days of such treatment.
Pronunciation: moRE-feen SULL-fate Class: Opioid analgesic.
CSA Schedule 2 High potential for abuse.
Morphine distributes to skeletal muscle, kidneys, liver, intestinal tract, lungs, spleen, and brain; crosses the placental membrane and is found in breast milk.
WADA Class WADA Anti-Doping Classification.
Roxanol 100 - Solution 100 mg per 5 mL.